Theracle is developing an implantable device to enable direct, targeted drug delivery to the brain for the treatment of glioblastoma multiforme (GBM), an aggressive and lethal brain cancer with an average survival of just 15 months. To date, drug delivery to the brain has been constrained by the blood-brain barrier and dose-limiting toxicities from IV or oral drugs. By enabling a new drug delivery modality, the Theracle device has the potential to revolutionize treatment of GBM and improve clinical outcomes.
Our technology was developed at InCube Labs, a life science R&D lab founded by prolific healthcare innovator and entrepreneur, Mir Imran, in partnership with Dr. Jeffrey Bruce, a neurosurgeon at Columbia University Medical Center. We are actively exploring partnerships and collaborations with companies developing novel drugs for the treatment of GBM.